Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
提供了一种具有作为
尿激酶非共价
抑制剂活性并具有减少或抑制血管形成活性的新化合物。这些化合物具有P1基团,其具有酰胺基团或
胍基团或其衍
生物。这些化合物在体外用于监测纤溶酶原激活剂
水平,在体内用于治疗通过抑制
尿激酶或减少其活性而得到缓解的疾病症状,并用于治疗血管形成与病理病况相关的病理病况。